CN1061375C - Using allogeneic promoter to express transparent Tremellineae haemoglobin in streptomycete - Google Patents
Using allogeneic promoter to express transparent Tremellineae haemoglobin in streptomycete Download PDFInfo
- Publication number
- CN1061375C CN1061375C CN96116433A CN96116433A CN1061375C CN 1061375 C CN1061375 C CN 1061375C CN 96116433 A CN96116433 A CN 96116433A CN 96116433 A CN96116433 A CN 96116433A CN 1061375 C CN1061375 C CN 1061375C
- Authority
- CN
- China
- Prior art keywords
- vgb
- promoter
- plasmid
- gene
- streptomyces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241001655322 Streptomycetales Species 0.000 title claims 3
- 230000000735 allogeneic effect Effects 0.000 title 1
- 239000013612 plasmid Substances 0.000 claims abstract description 23
- 108700025158 Vitreoscilla hemoglobin Proteins 0.000 claims description 3
- 239000012634 fragment Substances 0.000 abstract description 12
- 241000187747 Streptomyces Species 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 108010054147 Hemoglobins Proteins 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 102000001554 Hemoglobins Human genes 0.000 abstract description 4
- 206010047642 Vitiligo Diseases 0.000 abstract description 4
- 210000004276 hyalin Anatomy 0.000 abstract description 2
- 101000796211 Streptomyces antibioticus Tyrosinase cofactor Proteins 0.000 abstract 2
- 101150112266 vgb gene Proteins 0.000 description 21
- 102000012410 DNA Ligases Human genes 0.000 description 7
- 108010061982 DNA Ligases Proteins 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000828254 Streptomyces lividans TK24 Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000863000 Vitreoscilla Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 108010080972 Catechol 2,3-dioxygenase Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229930188070 thiostrepton Natural products 0.000 description 1
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 description 1
- 229940063214 thiostrepton Drugs 0.000 description 1
- NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明在证明透明颤菌血红蛋白基因(vgb)启动子在链霉菌中无作用后,构建了一个能在链霉菌中表达透明颤菌血红蛋白(VHb)的质粒pFW201,将透明颤菌血红蛋白基因(vgb)启动子去掉后插入链霉菌质粒pIJ702上ORF438启动子下游,去掉ORF438启动子和透明颤菌血红蛋白基因之间含ATG的DNA片段,再将这一嵌合基因克隆至pIJ699,得到能有效表达透明颤菌血红蛋白,并能经胰蛋白胨诱导的质粒pFW201。The present invention has constructed a plasmid pFW201 capable of expressing Vitiligo hemoglobin (VHb) in Streptomyces after proving that the Vitiligo hemoglobin gene (vgb) promoter has no effect in Streptomyces. ) promoter was removed and then inserted into the downstream of the ORF438 promoter on Streptomyces plasmid pIJ702, the ATG-containing DNA fragment between the ORF438 promoter and the Vitiligo hyaline hemoglobin gene was removed, and the chimeric gene was cloned into pIJ699 to obtain an effective expression of transparent vitriol hemoglobin, and tryptone-inducible plasmid pFW201.
Description
本发明涉及一类能在链霉菌中表达透明颤菌血红蛋白(Vitreoscilla haemoglobin,VHb)的质粒,属于生物工程领域。The invention relates to a kind of plasmid capable of expressing Vitreoscilla haemoglobin (VHb) in Streptomyces, belonging to the field of bioengineering.
链霉菌及相近的菌用来生产许多种抗生素,如四环素、红霉素等。高密度链霉菌发酵物的高粘度特性使抗生素生产过程中的供氧成为一个主要问题。作为次生代谢物,抗生素的合成通常对氧气的供给又十分敏感。以前主要通过反应器的优化、通富氧空气和添加某些氧气助溶剂来满足微生物的氧耗。Streptomyces and related bacteria are used to produce many kinds of antibiotics, such as tetracycline, erythromycin, etc. The highly viscous nature of Streptomyces hyperdensity ferments makes oxygen supply a major concern during antibiotic production. As secondary metabolites, the synthesis of antibiotics is usually very sensitive to the supply of oxygen. In the past, the oxygen consumption of microorganisms was mainly met by optimizing the reactor, passing oxygen-enriched air, and adding some oxygen co-solvents.
1988年,由原核的透明颤菌(Vitreoscilla spp.)克隆到透明颤菌血红蛋白基因(Vitreoscilla haemoglobin gene,vgb),并在大肠杆菌中进行了表达,研究了其低氧诱导的特性。在大肠杆菌和真菌系统中证明导入vgb基因可在细胞水平改善供氧和提高产生ATP的效率。Magnolo等在天蓝链霉菌及变青链霉菌中表达了VHb,结果表明将vgb引入好氧的工业微生物中能起到更有效地利用氧,降低能耗,促进生长,增加产品产量的有益作用。但是Magnolo等构建的表达质粒pWLD5和pWLD10不能确切地说明vgb表达的关键问题:vgb基因启动子在链霉菌中能否起作用,VHb的表达不能通过诱导达到更高的水平,质粒上含过多的非必要异源基因片段也降低了其实用性。本发明中以质粒pIJ4083-pro(本发明构建)证明了vgb天然的启动子在变青链霉菌(Streptomyces lividans)TK24中不起作用。In 1988, the Vitreoscilla hemoglobin gene (Vitreoscilla haemoglobin gene, vgb) was cloned from the prokaryotic Vitreoscilla spp. and expressed in Escherichia coli to study its hypoxia-induced characteristics. In Escherichia coli and fungal systems, it has been proved that the introduction of vgb gene can improve oxygen supply and increase the efficiency of ATP production at the cellular level. Magnolo et al. expressed VHb in Streptomyces coelicolor and Streptomyces lividans, and the results showed that the introduction of vgb into aerobic industrial microorganisms can play a more effective role in utilizing oxygen, reducing energy consumption, promoting growth, and increasing product yield. However, the expression plasmids pWLD5 and pWLD10 constructed by Magnolo et al. cannot exactly explain the key issues of vgb expression: whether the vgb gene promoter can function in Streptomyces, the expression of VHb cannot be induced to a higher level, and the plasmid contains too much Non-essential heterologous gene segments also reduce their usefulness. In the present invention, the plasmid pIJ4083-pro (constructed by the present invention) is used to prove that the natural promoter of vgb does not work in Streptomyces lividans TK24.
本发明旨在提供一种能够在链霉菌中高水平表达血红蛋白的基因工程质粒。本发明的目的是这样实现的:将vgb基因(D.A.Webster博士惠赠)的天然启动子去掉,插入异源启动子下游后得到能有效表达VHb的质粒。具体地说是将去掉天然启动子的vgb基因克隆到质粒pIJ702(焦瑞身先生惠赠)上ORF438(开放阅读框架438)内的SphⅠ-BglⅡ位点,与ORF438同向,得到pIJ702-vgb′。SphⅠ位点内的ATG正好是ORF438的翻译启始密码,进一步去掉ORF438启动子与vgb ORF(血红蛋白基因开放阅读框架)之间含ATG的DNA片段,将二者连成嵌合基因,得到质粒pFW2。再将此嵌合基因克隆至链霉菌质粒pIJ699(焦瑞身先生惠赠)得到质粒pFW201。本发明构建的质粒pFW201上,pIJ699所带的终止子消除了质粒上其他基因片段对ORF438启动子表达的影响。此启动子可用胰蛋白胨诱导,pFW201应可在需要时达到更高的VHb表达水平。这几个VHb表达质粒均不含除vgb之外的非链霉菌DNA片段,同时去掉了vgb5′和3′端的多余片段,从而降低了被宿主菌限制的可能性。将该质粒引入用于抗生素生产的链霉菌,能较大幅度提高抗生素产量,降低能耗。The invention aims to provide a genetically engineered plasmid capable of high-level expression of hemoglobin in streptomyces. The purpose of the present invention is achieved as follows: the natural promoter of the vgb gene (gifted by Dr. D.A. Webster) is removed, and a plasmid capable of effectively expressing VHb is obtained after inserting the downstream of the heterologous promoter. Specifically, the vgb gene with the natural promoter removed was cloned into the SphI-BglII site in ORF438 (open reading frame 438) on the plasmid pIJ702 (gifted by Mr. Jiao Ruishen), in the same direction as ORF438, to obtain pIJ702-vgb'. The ATG in the SphⅠ site is just the translation initiation code of ORF438, further remove the ATG-containing DNA fragment between the ORF438 promoter and the vgb ORF (hemoglobin gene open reading frame), connect the two into a chimeric gene, and obtain the plasmid pFW2 . The chimeric gene was then cloned into Streptomyces plasmid pIJ699 (gifted by Mr. Jiao Ruishen) to obtain plasmid pFW201. On the plasmid pFW201 constructed in the present invention, the terminator carried by pIJ699 eliminates the influence of other gene fragments on the plasmid on the expression of the ORF438 promoter. This promoter is tryptone inducible and pFW201 should allow higher VHb expression levels if desired. These several VHb expression plasmids do not contain non-streptomyces DNA fragments except vgb, and at the same time, redundant fragments at the 5' and 3' ends of vgb are removed, thereby reducing the possibility of being restricted by host bacteria. The introduction of the plasmid into the Streptomyces used for antibiotic production can greatly increase the output of antibiotics and reduce energy consumption.
在以下实施例中对发明作进一步的详细描述:The invention is described in further detail in the following examples:
图1是质粒pIJ4083-pro的构建示意图。Figure 1 is a schematic diagram of the construction of plasmid pIJ4083-pro.
图2是质粒pOK12-vgb′的构建示意图。Fig. 2 is a schematic diagram of the construction of plasmid pOK12-vgb'.
图3是质粒pFW201的构建示意图。Fig. 3 is a schematic diagram of the construction of plasmid pFW201.
图4是变青链霉菌TK24中表达vHb活力图。其中a.TK24/pIJ702作为阴性对照,b.TK24/pFW201Fig. 4 is a graph showing the activity of vHb expressed in Streptomyces lividans TK24. Where a.TK24/pIJ702 is used as negative control, b.TK24/pFW201
图中:Amp为氨苄青霉素抗性基因,tsr为硫链丝菌素抗性基因,xy1E为邻苯二酚2,3-双加氧酶基因,Km为卡那霉素抗性基因,mel为酪氨酸酶基因,PoRF438为开放阅读框架438启动子,ter为终止子,AatⅡ、AflⅡ、BamHⅠ、BclⅠ、BglⅡ、EcoRⅠ、EcoRV、HindⅢ、SphⅠ等为限制性内切酶,OD为光密度,nm为纳米。In the figure: Amp is the ampicillin resistance gene, tsr is the thiostrepton resistance gene, xy1E is the catechol 2,3-dioxygenase gene, Km is the kanamycin resistance gene, mel is Tyrosinase gene, P oRF438 is the open reading frame 438 promoter, ter is the terminator, AatⅡ, AflⅡ, BamHI, BclⅠ, BglⅡ, EcoRI, EcoRV, HindⅢ, SphⅠ, etc. are restriction enzymes, OD is optical density , nm is nanometer.
实施例1,质粒pIJ4083-pro的构建。Example 1, construction of plasmid pIJ4083-pro.
参见图1。pUC21-vgb(本实验室保存)上含vgb基因的透明颤菌DNA片段长约1.4kb,方向为HindⅢ到BamHⅠ,HindⅢ与AflⅡ之间为启动子,AflⅡ与AatⅡ之间为ORF。将pUC21-vgb上1.4kb的HindⅢ-BamHⅠ片段切下,与同样酶切的起动子探针质粒pIJ4083(邓子新先生惠赠)用T4 DNA连接酶连接,转化变青链霉菌TK24(朱宝泉先生惠赠)后得到pIJ4083-vgb,BamHⅠ和AflⅡ双酶切pIJ4083-vgb,Klenow酶补平,冻融法回收大片段,T4 DNA连接酶连接后转化TK24得到pIJ4083-pro。See Figure 1. The DNA fragment of Vitiligo hyaline containing the vgb gene on pUC21-vgb (preserved in our laboratory) is about 1.4kb in length, the direction is from HindⅢ to BamHI, the promoter is between HindⅢ and AflⅡ, and the ORF is between AflⅡ and AatⅡ. Cut out the 1.4kb HindⅢ-BamHI fragment on pUC21-vgb, connect it with the promoter probe plasmid pIJ4083 (gifted by Mr. Deng Zixin) with the same restriction enzyme digestion, and use T4 DNA ligase to transform Streptomyces lividans TK24 (gifted by Mr. Zhu Baoquan) To obtain pIJ4083-vgb, pIJ4083-vgb was digested with BamHI and AflⅡ, filled with Klenow enzyme, and the large fragment was recovered by freeze-thaw method. After ligation with T4 DNA ligase, TK24 was transformed to obtain pIJ4083-pro.
实施例2,vgb启动子在TK24中无功能。Example 2, the vgb promoter is not functional in TK24.
向TK24/pIJ4083-pro在R2YE平板上长出的菌落滴加0.2mol/L邻苯二酚不显黄色,即无xy1E基因编码的邻苯二酚2,3-双加氧酶活力;培养TK24/pIJ4083-pro至对数中期后以保鲜膜封口实现低氧诱导,12小时后真空抽滤收集菌体,悬浮于100mmol/L、pH7.5的磷酸缓冲液中,于4℃超声破碎,10,000转/分离心10分钟后取上清。收集菌体制成无细胞抽提液。取3ml无细胞抽提液,加入50μl 0.2mol/L邻苯二酚溶液,避光于30℃保温10分钟,测定375nm处的光吸收,未能测到邻苯二酚2,3-双加氧酶酶活,表明vgb启动子在TK24中不能带动xy1E基因的转录,即无功能。Adding 0.2mol/L catechol dropwise to the colony grown on the R 2 YE plate by TK24/pIJ4083-pro does not show yellow color, that is, there is no catechol 2,3-dioxygenase activity encoded by the xy1E gene; Cultivate TK24/pIJ4083-pro to the mid-logarithmic phase and seal with plastic wrap to induce hypoxia. After 12 hours, collect the bacteria by vacuum filtration, suspend in 100mmol/L, pH7.5 phosphate buffer, and ultrasonically break at 4°C , centrifuge at 10,000 rpm for 10 minutes and take the supernatant. The bacteria were collected to make a cell-free extract. Take 3ml of cell-free extract, add 50μl 0.2mol/L catechol solution, keep it in the dark at 30°C for 10 minutes, measure the light absorption at 375nm, no catechol 2,3-bisaddition can be detected Oxygenase activity indicates that the vgb promoter cannot drive the transcription of the xy1E gene in TK24, that is, it has no function.
实施例3,质粒pOK12-vgb′的构建。Example 3, construction of plasmid pOK12-vgb'.
参见图2。以AflⅡ酶切pUC21-vgb,Klenow酶补平,再以BamH Ⅰ酶切,冻融回收1.3kb的vgb′(去掉天然起动子的vgb基因称为vgb′),与经BamH Ⅰ和EcoR V双酶切的pWSK129(本实验室保存)以T4 DNA连接酶连接,转化大肠杆菌DH5a(本实验室保存)后得到pWSK129-vgb′。HindⅢ和AatⅡ双酶切pWSK129-vgb′,冻融回收800bp的vgb′,与经HindⅢ和AatⅡ双酶切的pOK12(本实验室保存)以T4 DNA连接酶连接,转化大肠杆菌DH5a后得到pOK12-vgb′。See Figure 2. pUC21-vgb was digested with AflⅡ, filled with Klenow enzyme, then digested with BamH Ⅰ, and the 1.3kb vgb' (the vgb gene with the natural promoter removed is called vgb') was recovered by freezing and thawing, and combined with BamH Ⅰ and EcoR V double Digested pWSK129 (preserved in our laboratory) was ligated with T4 DNA ligase, and transformed into Escherichia coli DH5a (preserved in our laboratory) to obtain pWSK129-vgb'. HindⅢ and AatⅡ double enzyme digestion of pWSK129-vgb′, freeze-thaw recovery of 800bp vgb′, and HindⅢ and AatⅡ double enzyme digestion pOK12 (preserved in our laboratory) was ligated with T4 DNA ligase, transformed into Escherichia coli DH5a to obtain pOK12- vgb'.
实施例4,质粒pFW201的构建。Example 4, construction of plasmid pFW201.
参见图3。SphⅠ和BamHⅠ双酶切pOK12-vgb′,冻融回收800bp的vgb′片段并与SphⅠ和BglⅡ双酶切的pIJ702以T4 DNA连接酶连接,转化TK24后得到pIJ702-vgb′,HindⅢ和SphⅠ双酶切pIJ702-vgb′,T4 DNA多聚酶切平与补平大片段两端,T4 DNA连接酶连接后转化TK24得到pFW2,BclⅠ酶切pFW2,冻融回收2.19kb的含ORF438启动子和vgb′的片段,EcoRⅠ和BglⅡ双酶切pIJ699,冻融回收5kb的BglⅡ-BglⅡ片断,将二者以T4 DNA连接酶连接,转化TK24后得到pFW201。(S.lividans TK24/pFW201,存放标记为CCTCC M96007中国·武汉·武汉大学校内·中国典型培养物保藏中心)。See Figure 3. SphⅠ and BamHI double digested pOK12-vgb′, freeze-thawed 800bp vgb′ fragment was recovered and ligated with SphⅠ and BglⅡ double digested pIJ702 with T4 DNA ligase, transformed into TK24 to obtain pIJ702-vgb′, HindⅢ and SphⅠ double enzyme Cut pIJ702-vgb′, T4 DNA polymerase cuts and fills both ends of the large fragment, T4 DNA ligase ligates and transforms TK24 to obtain pFW2, digests pFW2 with BclⅠ, recovers a 2.19kb fragment containing ORF438 promoter and vgb′ by freezing and thawing , EcoRI and BglII double-digested pIJ699, freeze-thawed to recover the 5kb BglII-BglII fragment, connected the two with T4 DNA ligase, and transformed TK24 to obtain pFW201. (S.lividans TK24/pFW201, stored under the symbol CCTCC M96007 China·Wuhan·Wuhan University Campus·China Center for Type Culture Collection).
实施例5,含血红蛋白表达质粒的TK24中VHb活力的测定。Example 5, Determination of VHb activity in TK24 containing hemoglobin expression plasmid.
参见图4。同前制无细胞抽提液,以差分光谱法测定菌体中VHb的活力,经光谱扫描在420nm处有特征吸收峰者为有VHb表达。可见TK24/pFW201在420nm附近有吸收峰,即能检测到VHb活力,对照TK24/pIJ702没有。See Figure 4. The cell-free extract was the same as that prepared before, and the activity of VHb in the bacteria was measured by differential spectroscopy, and those with characteristic absorption peaks at 420nm by spectral scanning were considered to have VHb expression. It can be seen that TK24/pFW201 has an absorption peak near 420nm, that is, the VHb activity can be detected, but the control TK24/pIJ702 does not.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96116433A CN1061375C (en) | 1996-07-19 | 1996-07-19 | Using allogeneic promoter to express transparent Tremellineae haemoglobin in streptomycete |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96116433A CN1061375C (en) | 1996-07-19 | 1996-07-19 | Using allogeneic promoter to express transparent Tremellineae haemoglobin in streptomycete |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1171444A CN1171444A (en) | 1998-01-28 |
| CN1061375C true CN1061375C (en) | 2001-01-31 |
Family
ID=5123537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96116433A Expired - Fee Related CN1061375C (en) | 1996-07-19 | 1996-07-19 | Using allogeneic promoter to express transparent Tremellineae haemoglobin in streptomycete |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1061375C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102061295A (en) * | 2010-09-20 | 2011-05-18 | 深圳大学 | Vitreoscilla hemoglobin gene expression box and method for improving yield of saccharifying enzyme produced by aspergillus niger |
| CN102181470B (en) * | 2011-03-08 | 2013-07-03 | 上海交通大学 | The method and its plasmid for increasing the production of Streptomyces antibiotics |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1055952A (en) * | 1990-04-21 | 1991-11-06 | 赫彻斯特股份公司 | Method for preparing foreign protein with Streptomyces |
| CN1022345C (en) * | 1989-10-25 | 1993-10-06 | 有限会社日田-穆尔 | Pipe joint |
-
1996
- 1996-07-19 CN CN96116433A patent/CN1061375C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1022345C (en) * | 1989-10-25 | 1993-10-06 | 有限会社日田-穆尔 | Pipe joint |
| CN1055952A (en) * | 1990-04-21 | 1991-11-06 | 赫彻斯特股份公司 | Method for preparing foreign protein with Streptomyces |
Non-Patent Citations (1)
| Title |
|---|
| BIOTECHNOCOGY9(5) 1991.1.1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1171444A (en) | 1998-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ohta et al. | Genetic improvement of Escherichia coli for ethanol production: chromosomal integration of Zymomonas mobilis genes encoding pyruvate decarboxylase and alcohol dehydrogenase II | |
| Holsters et al. | Transfection and transformation of Agrobacterium tumefaciens | |
| CN1061375C (en) | Using allogeneic promoter to express transparent Tremellineae haemoglobin in streptomycete | |
| EP1078991A8 (en) | Methods for producing L-amino acids | |
| CN106222190A (en) | A kind of bacillus subtilis logarithmic (log) phase expression system | |
| CN112143691A (en) | Escherichia coli zjut-bvr and its application in the preparation of biliverdin reductase | |
| US5888786A (en) | Method for producing 2-keto-L-gulonic acid | |
| CN102952814A (en) | Recombined heat-resisting short-chain dehydrogenase gene, codase, carrier, engineering bacterium and application | |
| CN104152425B (en) | A kind of thermophilic esterase and the application in degraded PAEs thereof | |
| Richmond et al. | Stimulatory effects of calcium carbonate on butanol production by solventogenic Clostridium species. | |
| Liu et al. | Directed evolution of an exoglucanase facilitated by a co-expressed β-glucosidase and construction of a whole engineered cellulase system in Escherichia coli | |
| Liu et al. | Co-production of a whole cellulase system in Escherichia coli | |
| Zhou et al. | Butanol production from glycerol by recombinant Escherichia coli | |
| ES2611977T3 (en) | Modification of the pnp gene for improved use of xylose in zymomonas | |
| Mullaney et al. | Bacteriophage T4 capsid packaging and unpackaging of DNA and proteins | |
| CN104560741B (en) | A kind of temperature control starts the structure of the aspergillus niger genetic engineering bacterium of expression cellulose excision enzyme | |
| RU2088667C1 (en) | Method of microbiological hydroxylation of methyl groups of aromatic 5- and 6-membered heterocycles, recombinant plasmid dna pl04, recombinant plasmid dna pl05, strain of microorganism escherichia coli used for producing hydroxymethyl derivatives of aromatic 5- or 6-membered heterocycles and strain of microorganism pseudomonas putida used for producing hydroxymethyl derivatives of aromatic 5- or 6-membered heterocycles | |
| CN104560800B (en) | A kind of phenylpyruvic acid reductase and its application in asymmetric syntheses (R) phenyllactic acid | |
| US4612287A (en) | Plasmids containing a gene coding for a thermostable pullulanase and pullulanase-producing strains of Escherichia coli and Bacillus subtilis containing the plasmids | |
| Chen et al. | Organic acid and solvent production: butanol, acetone, and isopropanol; 1, 3-and 1, 2-propanediol production; and 2, 3-butanediol production | |
| CN113789338A (en) | A kind of catalase active inclusion body and its application | |
| JPS62122585A (en) | Host-vector system | |
| CN111979167A (en) | A kind of recombinant clostridium acetobutylicum for efficient conversion of straw biomass carbon source and its construction method and application | |
| CN106467903B (en) | A kind of bacillus licheniformis engineering bacteria and its construction method suitable for pulping process | |
| CN112301072B (en) | Method for improving yield of ascomycin by using polyhydroxybutyrate as intracellular carbon depot |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |